2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1058

Prevalence of Comorbidities in Spondyloarthritis and Evaluation of Their Monitoring: Results of the International Cross-Sectional ASAS-Comospa Study
Abstract Number: 2306

Prevalence of Fibromyalgia in Inflammatory Rheumatic Disease. Single-Center Cross-Sectional Study in 691 Patients
Abstract Number: 2239

Prevalence of Gout and Hyperuricemia and Association with Fat Mass and Fat Free Mass: Results from a Population-Based Study
Abstract Number: 335

Prevalence of Hand Osteoarthritis and Factors Associated with Pain in Korean Farmers
Abstract Number: 1232

Prevalence of Idiopathic Inflammatory Myopathies in Sweden in 2012 – a National Register Study
Abstract Number: 1716

Prevalence of Joint Symptoms and Frequency of Joint Exams for Patients with Plaque Psoriasis without Confirmed Psoriatic Arthritis: A US Analysis
Abstract Number: 1305

Prevalence of MR-Detected Ramris-Defined Erosions in the General Population
Abstract Number: 1704

Prevalence of Obesity and Metabolic Syndrome in Patients with Axial Spondyloarthritis
Abstract Number: 1437

Prevalence of Pain, Its Impact and Management in a Population-Based Cohort of Patients with Rheumatoid Arthritis: Data from the Australian Rheumatology Association Database
Abstract Number: 1723

Prevalence of Sacroiliitis in Inflammatory Bowel Disease Using a Standardized CT Scoring System
Abstract Number: 841

Prevalence of Systemic Sclerosis in Primary Biliary Cirrhosis Using the New ACR/EULAR Classification Criteria
Abstract Number: 2637

Prevalence of Unacceptable Pain and the Risk of Fatigue and Sleeping Problems in Early Rheumatoid Arthritis Patients
Abstract Number: 1501

Prevalence of Unassessed and Uncontrolled Cardiovascular Disease Risk Factors Among Rheumatoid Arthritis Patients in an Academic Rheumatology Practice
Abstract Number: 367

Prevention and Treatment of Bone Loss Following Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis
Abstract Number: 1046

Previous Biologic Disease-Modifying Antirheumatic Drug (bDMARD) Exposure and Efficacy and Safety Analysis from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].